The Janssen name came from Dr. Paul Janssen, who founded Janssen Pharmaceutica N.V. in 1953.

Our foundations

In 2010, the pharmaceutical companies of Johnson & Johnson adopted a common identity—the Janssen Pharmaceutical Companies of Johnson & Johnson. Coming together as “One Team” strengthened our connection as a global organisation. The name embodied our commitment to finding solutions for patients by advancing science and medicine.

Dr. Paul, as he was known throughout the global scientific community, was an exceptionally gifted and passionate scientist who revolutionised modern medicine and inspired a new generation of researchers. His life was dedicated to creating medicines that met the unmet needs of millions of patients. Janssen Pharmaceutica N.V. was acquired by Johnson & Johnson in 1961. That, and earlier acquisitions of McNeil Pharmaceutical and Cilag Chemie in 1959, became the foundation of our pharmaceutical business today.

New identity, same purpose

In September 2023, The Janssen Pharmaceutical Companies of Johnson & Johnson became Johnson & Johnson Innovative Medicine. Our new brand truly reflects the best of who we are and what we do.

Patients inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science and compassion, we confidently address some of the most complex diseases of our time and unlock the potential medicines of tomorrow.

Our diverse portfolio spans multiple therapeutic areas — Oncology, Haematology, Immunology, Neuroscience, Pulmonary Hypertension and Specialty Ophthalmology.

We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way.